Moby summary of NovoCure Limited's Q4 2025 earnings call ...

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most ...

Optune Pax® with the chemotherapy combination of gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer.

Management issued guidance of $675 million to $705 million in net revenue for 2026, assuming Optune Gio net revenue growth in the low to mid-single digits and $15 million to $25 million in net revenue ...

For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer​.

Novocure NVCR recently announced the FDA approval for its portable therapeutic device, Optune Pax, for treating adult ...

The FDA approved Optune Pax (Novocure), a first-in-class portable device that delivers tumor-treating fields (TTFields) to ...

FDA leaders framed the approval as a step forward for a cancer that has seen few therapeutic breakthroughs, stressing that ...

Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer ...

Optune Pax is a portable medical device that delivers TTFields non-invasively via wearable arrays to disrupt electrical processes essential for cancer cell division.

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance ...